Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
Open Access
- 22 April 2010
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 10 (1) , 40
- https://doi.org/10.1186/1471-230x-10-40
Abstract
FibroTest and elastography have been validated as biomarkers of liver fibrosis in the most frequent chronic liver diseases and in the fibrosis screening of patients with diabetes. One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population.Keywords
This publication has 33 references indexed in Scilit:
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumptionEuropean Journal of Gastroenterology & Hepatology, 2009
- Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease†Hepatology, 2008
- Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis MarkersPLOS ONE, 2008
- An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral LoadPLOS ONE, 2008
- Diagnosis and Quantitation of FibrosisGastroenterology, 2008
- Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-AnalysisGastroenterology, 2008
- Colonoscopy in Colorectal-Cancer Screening for Detection of Advanced NeoplasiaNew England Journal of Medicine, 2006
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis CHepatology, 2003
- Sampling variability of liver fibrosis in chronic hepatitis CHepatology, 2003